Carcinoma in situ of skin of left lower limb, including hip in India: Symptoms, Causes & Treatment | aihealz
ICD variantCarcinoma in situ of skin of left lower limb, including hip is a specific ICD-10 coded subtype of Carcinoma In Situ. The clinical content below covers Carcinoma In Situ in general.
HematologycriticalICD-10 · D04.72
Carcinoma in situ of skin of left lower limb, including hip.Care & specialists in India
In India, carcinoma in situ of skin of left lower limb, including hip is managed by hematologists. Carcinoma in situ (CIS) is the earliest histologic stage of cancer, defined by malignant cells confined to the epithelium without breach of the basement membrane that separates them from underlying tissue and blood vessels. Because invasion has not occurred, CIS cannot metastasize and has a 5-year survival above 95% across most sites with appropriate treatment.
Bowen disease — a well-defined erythematous scaly plaque on sun-exposed skin, squamous carcinoma in situ. · Credit: Wikimedia Commons · CC BY-SA 3.0
aliases · Carcinoma in situ (stage 0 cancer)· Carcinome in situ· Carcinoma in situ· Karzinom in situ· reviewed May 13, 2026
EB
Reviewed by AIHealz Medical Editorial Board · HematologyLast reviewed May 13, 2026
Carcinoma in situ (ICD-10: D00-D09) is a histopathologic diagnosis defined by malignant epithelial cells that show the full cytologic and architectural features of cancer but remain confined to the epithelium of origin, without breaching the underlying basement membrane. Because invasion of stroma is required for access to blood vessels and lymphatics, CIS has no metastatic potential at the time of diagnosis. The 8th edition AJCC staging classifies CIS as stage 0 disease and assigns it a Tis (T-in-situ) designation across most cancer sites. The concept is unified across anatomy: ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) in the breast; cervical intraepithelial neoplasia grade 3 (CIN3) — by current terminology high-grade squamous intraepithelial lesion (HSIL) at the cervix; Bowen disease (squamous cell carcinoma in situ) in the skin; CIS of bladder urothelium; high-grade dysplasia of esophagus, stomach, and colon (which the WHO 2019 classification now formally equates with carcinoma in situ); and CIS of the larynx, vulva, anus, prostate, and other organs.
key facts
Prevalence
~64,000 DCIS cases per year in the US (SEER 2020); ~250,000 high-grade cervical intraepithelial neoplasia cases per year
Demographics
DCIS predominantly in women aged 40-70; CIN in sexually active women aged 20-50; Bowen disease and CIS bladder in adults aged 60-80
Avg. age
Median age varies by site: DCIS 60, CIN 25-35, Bowen disease 65-75, CIS bladder 65-75
Global cases
Tens of millions worldwide across all sites; the largest single category is HPV-associated CIN, with estimated incidence over 1 million per year globally
§ 02
How you might notice it
Bowen disease — a well-defined erythematous scaly plaque on sun-exposed skin, squamous carcinoma in situ. · Credit: Wikimedia Commons · CC BY-SA 3.0
The key symptoms of Carcinoma in situ of skin of left lower limb, including hip are: Most carcinomas in situ are asymptomatic and detected only by imaging or cytologic screening — this is the dominant clinical fact about the diagnosis., DCIS may present as a palpable breast lump or new nipple discharge in 10-20% of cases, but most are detected as microcalcifications on routine mammography., Cervical intraepithelial neoplasia is almost always asymptomatic and detected on cervical screening (cytology, HPV testing, or both); abnormal bleeding suggests invasive disease., Bowen disease appears as a slowly enlarging, red, scaly, well-defined patch or plaque on sun-exposed skin, often mistaken for eczema or psoriasis for months., Bladder carcinoma in situ may present with painful urination, urinary frequency, and microscopic or visible hematuria, sometimes resembling refractory urinary tract infection., High-grade dysplasia in Barrett esophagus is usually asymptomatic and detected during surveillance endoscopy in patients with known long-standing gastroesophageal reflux disease., Anal and vulvar intraepithelial neoplasia can cause itching, burning, or a visible lesion noted by patient or clinician..
01Most carcinomas in situ are asymptomatic and detected only by imaging or cytologic screening — this is the dominant clinical fact about the diagnosis.
02DCIS may present as a palpable breast lump or new nipple discharge in 10-20% of cases, but most are detected as microcalcifications on routine mammography.
§ 03
How it’s diagnosed
High-grade ductal carcinoma in situ — malignant cells confined within a breast duct without invasion. · Credit: Nephron / Wikimedia Commons · CC BY-SA 3.0
diagnosis
Diagnosis of carcinoma in situ is histopathologic, requiring tissue biopsy with confirmation that malignant epithelial cells are present without invasion through the basement membrane. The diagnostic pathway varies by site, but in every case starts with screening detection or symptom-driven evaluation followed by targeted biopsy. For DCIS, screening mammography identifies clustered microcalcifications, branching microcalcifications, or rarely a mass; stereotactic core needle biopsy provides tissue. Pathology characterizes grade (low, intermediate, high), architectural pattern (cribriform, micropapillary, solid, comedo), estrogen and progesterone receptor status, and HER2. For cervical intraepithelial neoplasia, cervical cytology (Pap test) and high-risk HPV testing are the screening tools; an abnormal screen triggers colposcopy with directed biopsy. The 2019 ASCCP risk-based management guidelines now stratify treatment by composite risk of CIN3+ rather than by single test result, reducing both overtreatment and undertreatment. For Bowen disease, dermatoscopic examination of a persistent scaly plaque is followed by shave or punch biopsy demonstrating full-thickness atypia of keratinocytes. For bladder CIS, urinary cytology has high sensitivity for high-grade urothelial lesions, and white-light cystoscopy supplemented by blue-light fluorescence cystoscopy with hexaminolevulinate improves detection of flat lesions. Biopsy of suspicious areas and random bladder mapping biopsies confirm the diagnosis. For Barrett esophagus, surveillance endoscopy with four-quadrant biopsies every 2 cm of Barrett segment detects high-grade dysplasia. Two expert gastrointestinal pathologists should confirm the diagnosis given the implications for treatment. Across all sites, immunohistochemistry and molecular profiling are increasingly used to predict progression risk and guide treatment intensity.
§ 04
Treatment & cost
medical treatments
✓Breast-conserving lumpectomy with whole-breast radiation (DCIS)
✓Loop electrosurgical excision procedure (LEEP) or cold-knife conization (CIN3)
✓Intravesical BCG induction and maintenance (bladder CIS)
surgical options
Mastectomy (DCIS)Local recurrence under 2% at 10 years; survival equivalent to lumpectomy plus radiation.
Radical cystectomy (refractory bladder CIS)5-year disease-free survival above 80% for non-muscle-invasive disease at cystectomy; recurrence in regional nodes or distant sites in under 20%.
Cold-knife conization (CIN3)Cure rate above 95% with negative margins; small risk of cervical insufficiency in subsequent pregnancy.
Wide local excision (Bowen disease, vulvar and anal CIS)5-year recurrence under 10% with negative margins.
§ 05
Causes & risk factors
known causes
Persistent high-risk human papillomavirus (HPV) infection
Drives the vast majority of cervical, anal, vulvar, vaginal, and oropharyngeal intraepithelial neoplasia. HPV E6 and E7 oncoproteins inactivate tumor suppressors p53 and Rb, allowing accumulation of mutations that produce dysplasia and eventually invasion if not cleared.
Cumulative ultraviolet radiation
The dominant cause of Bowen disease and other cutaneous squamous intraepithelial lesions. UV-induced C>T mutations accumulate over decades of sun exposure in keratinocytes, producing the high mutation burden seen in field-cancerized chronic sun-damaged skin.
Tobacco smoke and chemical carcinogens
Tobacco smoke contains aromatic amines and polycyclic hydrocarbons that drive urothelial CIS of bladder and renal pelvis. Occupational exposure to aromatic amines (rubber, dye, leather industries) is a further substantial driver of urothelial carcinoma in situ.
Chronic mucosal inflammation and metaplasia
Long-standing acid reflux causing Barrett esophagus, chronic Helicobacter pylori gastritis, ulcerative colitis affecting the colon, and chronic schistosomiasis affecting the bladder all create metaplastic and inflammatory environments from which carcinoma in situ can emerge.
Inherited tumor-suppressor gene mutations
Germline BRCA1, BRCA2, TP53 (Li-Fraumeni), and CDH1 mutations predispose to breast carcinoma in situ; APC and Lynch syndrome mutations predispose to colorectal high-grade dysplasia; PTEN mutations predispose to multiple intraepithelial lesions.
Hormonal exposure and reproductive factors
Estrogen receptor signaling supports ductal proliferation in the breast and is implicated in DCIS pathogenesis. Early menarche, late menopause, nulliparity, and exogenous estrogen exposure all modestly raise DCIS risk.
risk factors
§ 06
Living with it
01Receive HPV vaccination through age 26 and on a shared-decision basis from 27 to 45 to prevent high-grade cervical, anal, vulvar, and oropharyngeal intraepithelial neoplasia
02Attend recommended cervical screening every 3-5 years with cytology and high-risk HPV testing
03Attend recommended breast screening mammography from age 40-50 depending on risk and guideline jurisdiction
04Use daily broad-spectrum sunscreen SPF 30+, sun-protective clothing, and avoid tanning beds to reduce cutaneous CIS
05Stop smoking — substantially reduces bladder CIS, laryngeal CIS, and oral CIS risk over 10-15 years
recommended foods
•Mediterranean-style diet rich in vegetables, fruits, whole grains, olive oil, and fish — associated with lower overall cancer recurrence
•Adequate fiber from whole foods to support colon health and reduce colorectal recurrence
•Vitamin D-rich foods or supplementation to maintain 25-OH-D above 30 ng/mL
•
§ 07
When to seek help
why see a hematology
Carcinoma in situ should be managed by a site-appropriate specialist team. DCIS is managed by breast surgeons, medical oncologists, and radiation oncologists. CIN is managed by gynecologic oncologists or colposcopists. Bowen disease and other cutaneous CIS are managed by dermatologists and dermatologic surgeons. Bladder CIS is managed by urologic oncologists. Barrett high-grade dysplasia is managed by therapeutic gastroenterologists. Multidisciplinary tumor boards review complex cases. Genetic counseling is offered to patients with personal or family histories suggesting hereditary syndromes.
01Recurrence at the original site or development of new intraepithelial lesions in field-cancerized tissue
02Progression to invasive cancer, which is highly site-dependent: 3-5% over years for Bowen disease, 15-20% over 5 years for bladder CIS, 30-50% for high-grade DCIS, 30% over 30 years for CIN3
03Treatment-related complications: cervical insufficiency in pregnancy after deep conization, breast skin and lung effects of radiation, BCG sepsis or systemic mycobacterial infection, esophageal stricture after ablation
04Anxiety, depression, and quality-of-life burden of cancer diagnosis even when invasion has not occurred
05Overdiagnosis and overtreatment of indolent lesions that may never have progressed — particularly relevant in DCIS and low-grade cervical intraepithelial neoplasia
Ductal carcinoma in situ (DCIS) of breastMalignant ductal epithelial cells confined within the breast ducts. Most often detected as clustered microcalcifications on screening mammography. Subdivided into low, intermediate, and high nuclear grade, with progression risk strongly tied to grade and the presence of comedo necrosis.
Lobular carcinoma in situ (LCIS)Now considered a risk marker rather than a true precursor in the classic non-pleomorphic form. Confers a 1-2% per year lifetime risk of invasive breast cancer in either breast. Pleomorphic LCIS behaves more aggressively and is treated similarly to DCIS.
Cervical intraepithelial neoplasia (CIN3) / high-grade squamous intraepithelial lesion (HSIL)Full-thickness dysplastic change in cervical squamous epithelium driven by persistent high-risk HPV infection. Progresses to invasive cancer in approximately 30% over 30 years if untreated, but reverses in a small proportion.
Bowen disease (squamous cell carcinoma in situ of skin)Solitary or multiple slowly growing erythematous, scaly plaques most often on sun-exposed skin. Progression to invasive squamous cell carcinoma occurs in 3-5% of untreated lesions over years.
Carcinoma in situ of bladder urotheliumFlat, high-grade dysplastic urothelial cells with no papillary or invasive component. Often multifocal. Progression to muscle-invasive disease without treatment is 30-80% over 5-10 years.
High-grade dysplasia of Barrett esophagusConsidered equivalent to carcinoma in situ by WHO 2019 nomenclature. Progresses to invasive esophageal adenocarcinoma in approximately 7% per year without intervention.
Carcinoma in situ of larynx, vulva, anus, prostate, and othersSite-specific CIS at additional epithelial sites. Each has distinct natural history, screening method, and treatment, but shares the absence of basement-membrane breach and stage-0 designation.
Living with Carcinoma in situ of skin of left lower limb, including hip
Timeline
Recovery after CIS treatment varies by procedure: lumpectomy with radiation involves 4-6 weeks of daily radiation followed by full recovery over 8-12 weeks; LEEP for CIN3 recovers within 2-4 weeks with minimal bleeding; topical or photodynamic therapy for Bowen disease causes 2-4 weeks of inflammation and crusting with healing over 1-2 months; intravesical BCG induction runs over 6 weeks with maintenance over 1-3 years; endoscopic ablation of Barrett high-grade dysplasia requires multiple sessions 2-3 months apart with full eradication over 6-18 months. Surveillance follow-up continues for years across all sites.
Lifestyle
01Quit smoking, particularly important after bladder CIS diagnosis where smoking accelerates recurrence and progression
02Maintain a healthy body weight — obesity is independently associated with DCIS and post-treatment recurrence
03Limit alcohol to under 1 drink daily for women and 2 for men — independently raises breast cancer and oral CIS risk
04Manage gastroesophageal reflux with lifestyle measures and prescribed proton pump inhibitor therapy in Barrett patients
05Apply daily broad-spectrum sunscreen and reduce cumulative UV exposure after a Bowen disease diagnosis
06Adhere to surveillance schedules — imaging, cytology, endoscopy, or cystoscopy depending on site
Daily management
Complementary approaches
Active surveillance for low-risk DCIS (in clinical trials)The COMET, LORIS, and LORD trials are evaluating surveillance (imaging plus optional endocrine therapy) versus standard treatment for low-grade hormone-receptor-positive DCIS. Early data suggest acceptable short-term safety, but mature outcomes are pending. Discuss enrollment with your oncology team if you meet eligibility criteria.
HPV vaccinationAlthough not a treatment for established lesions, prophylactic HPV vaccination of cohort partners and after treatment of high-grade cervical lesions has been associated with lower recurrence rates in observational studies. Vaccination is recommended through age 26 and on a shared-decision basis from 27 to 45.
Choosing a doctor
Look for board certification in the relevant specialty, experience with carcinoma in situ specifically, and a multidisciplinary team approach. For DCIS, choose a center with breast-specific imaging, on-site pathology with subspecialty expertise, and access to clinical trials. For CIN, choose colposcopists trained to current ASCCP standards. For Bowen disease, prefer dermatologists with Mohs surgery available. For bladder CIS, prefer urologists with blue-light cystoscopy experience. For Barrett dysplasia, prefer high-volume endoscopists comfortable with endoscopic mucosal resection and radiofrequency ablation.
Carcinoma in situ is the earliest stage of cancer. Malignant cells are confined to the layer of tissue where they began and have not invaded through the basement membrane into underlying tissue or blood vessels. Because of this, carcinoma in situ cannot spread to lymph nodes or distant organs. Five-year survival is above 95% across most sites with appropriate treatment.
Is carcinoma in situ really cancer?▾▴
Carcinoma in situ has the cytologic features of cancer (abnormal nuclei, disorganized growth, loss of normal architecture) but lacks the invasion through the basement membrane that defines truly invasive cancer. Most cancer staging systems classify CIS as stage 0 — present but not yet invasive. The diagnostic and prognostic implications differ substantially from invasive cancer.
What is DCIS?▾▴
Ductal carcinoma in situ (DCIS) is carcinoma in situ of the breast — malignant cells confined within the milk ducts without invasion of surrounding breast tissue. It accounts for 25-30% of newly diagnosed breast cancers and is usually detected by clustered microcalcifications on screening mammography. Treatment includes lumpectomy plus radiation, sometimes mastectomy, and endocrine therapy for hormone-receptor-positive disease.
What is CIN3?▾▴
Cervical intraepithelial neoplasia grade 3 (CIN3), also called high-grade squamous intraepithelial lesion (HSIL), is carcinoma in situ of the cervix. Persistent high-risk HPV infection drives full-thickness dysplastic change in cervical epithelium. Treatment is usually loop electrosurgical excision procedure (LEEP) or cold-knife conization, with cure rates above 90% with negative margins.
What is Bowen disease?▾▴
Bowen disease is squamous cell carcinoma in situ of the skin — a slowly enlarging red, scaly patch on chronically sun-exposed skin most often in adults over 60. Untreated, it progresses to invasive squamous cell carcinoma in 3-5% of cases. Treatments include topical 5-fluorouracil, topical imiquimod, photodynamic therapy, cryotherapy, and surgical excision, with clearance rates of 75-95%.
What is CIS of the bladder?▾▴
Carcinoma in situ of the bladder is a flat, high-grade lesion of the urothelium without papillary or invasive components. Often multifocal and frequently associated with smoking, it presents with urinary frequency, dysuria, or hematuria. Treatment is intravesical Bacillus Calmette-Guérin (BCG) for 1-3 years; radical cystectomy is reserved for BCG-refractory disease.
Will carcinoma in situ turn into invasive cancer?▾▴
The risk depends on the site, grade, and treatment. Untreated CIN3 progresses to invasive cervical cancer in approximately 30% over 30 years. Untreated high-grade DCIS progresses to invasive breast cancer in 30-50%. Bowen disease progresses to invasive disease in 3-5%. Bladder CIS progresses to muscle-invasive disease in 30-80% over 5-10 years without treatment.
How is carcinoma in situ diagnosed?▾▴
Diagnosis requires tissue biopsy with histopathology that confirms malignant cells confined to the epithelium without basement-membrane breach. The biopsy is taken from a lesion detected by screening — mammography for DCIS, cytology and HPV testing for CIN, skin examination for Bowen disease, cystoscopy for bladder CIS, endoscopy for esophageal high-grade dysplasia.
Is treatment always needed for carcinoma in situ?▾▴
Most carcinoma in situ requires treatment because the risk of progression to invasive cancer is substantial. Active surveillance is being studied in low-risk DCIS through randomized trials (COMET, LORIS, LORD), with early data suggesting acceptable short-term safety. Outside trials, standard care for diagnosed CIS is treatment rather than observation.
Is carcinoma in situ curable?▾▴
Yes. Five-year survival exceeds 95% across most CIS sites with appropriate treatment. DCIS, CIN3, Bowen disease, bladder CIS, and high-grade Barrett dysplasia are all routinely cured by site-specific approaches. The main long-term concern is recurrence or new lesions in field-cancerized tissue, which is why surveillance after treatment is essential.
What is the survival rate for carcinoma in situ?▾▴
Five-year survival is above 95% across virtually all carcinoma in situ sites with appropriate treatment. Ten-year breast-cancer-specific mortality after treated DCIS is under 3%. Long-term mortality is driven mostly by subsequent invasive disease rather than the CIS itself, making adherence to surveillance and prevention strategies critical.
What causes carcinoma in situ?▾▴
Major causes include persistent high-risk HPV (for cervical, anal, vulvar, oropharyngeal CIS), cumulative ultraviolet exposure (cutaneous CIS), tobacco and chemical carcinogens (bladder, oral, laryngeal CIS), chronic inflammation and metaplasia (Barrett esophagus, colon dysplasia), and inherited tumor-suppressor mutations such as BRCA1/2 and Lynch syndrome.
Can carcinoma in situ come back?▾▴
Recurrence is possible at the original site or as new lesions in field-cancerized tissue. Recurrence rates are 5-15% over 10 years for treated DCIS, 5-10% for treated CIN3, 10-20% for Bowen disease, and 30-40% for bladder CIS. Surveillance schedules — imaging, cytology, cystoscopy, or endoscopy — are designed to detect recurrences early.
Is HPV vaccine effective against carcinoma in situ?▾▴
Yes. HPV vaccination reduces incidence of high-grade cervical, anal, vulvar, and oropharyngeal intraepithelial neoplasia by over 80% in cohorts vaccinated before HPV exposure. Vaccination is also recommended after treatment of HPV-associated lesions, where observational data suggest lower recurrence rates.
What does stage 0 cancer mean?▾▴
Stage 0 is the AJCC stage assigned to carcinoma in situ across most cancer sites. It signifies that malignant cells are present but have not invaded beyond the epithelium. Five-year survival is above 95% for stage 0 disease, and treatment is local rather than systemic. Stage 0 is the most favorable cancer stage.
How is DCIS treated?▾▴
Most DCIS is treated with breast-conserving lumpectomy plus whole-breast radiation, with endocrine therapy added for hormone-receptor-positive disease. Mastectomy is used for extensive multifocal DCIS, contraindications to radiation, BRCA1/2 carriers, or patient preference. Sentinel lymph node biopsy is added when invasion is suspected at surgery.
Do I need chemotherapy for carcinoma in situ?▾▴
Chemotherapy is generally not used for carcinoma in situ because the disease has not invaded blood vessels or lymphatics and cannot metastasize. Treatment is local — surgery, radiation, topical agents, intravesical therapy, or endoscopic resection. Endocrine therapy is used in hormone-receptor-positive DCIS as a chemopreventive measure rather than chemotherapy.
How is bladder carcinoma in situ treated?▾▴
Bladder CIS is treated with intravesical Bacillus Calmette-Guérin (BCG) — a 6-week induction course followed by maintenance therapy for 1-3 years. Complete response is achieved in 65-75% at 3 months. Radical cystectomy is reserved for BCG-refractory or BCG-intolerant disease and extensive multifocal CIS.
Can carcinoma in situ be detected by blood test?▾▴
There is currently no validated blood test for carcinoma in situ. Detection relies on site-specific screening: mammography for DCIS, cervical cytology and HPV testing for CIN, urinary cytology and cystoscopy for bladder CIS, skin examination for Bowen disease, and endoscopy for Barrett high-grade dysplasia. Blood-based multi-cancer early detection tests are an active research area but not yet validated for CIS.
What is the difference between dysplasia and carcinoma in situ?▾▴
Dysplasia refers to disordered cell growth with cytologic abnormalities of variable severity. High-grade or severe dysplasia is essentially synonymous with carcinoma in situ in many sites — the 2019 WHO classification formally equates high-grade dysplasia in Barrett esophagus, stomach, and colon with carcinoma in situ. Low-grade dysplasia is a milder precursor that may regress and does not require immediate treatment.
03Cervical intraepithelial neoplasia is almost always asymptomatic and detected on cervical screening (cytology, HPV testing, or both); abnormal bleeding suggests invasive disease.
04Bowen disease appears as a slowly enlarging, red, scaly, well-defined patch or plaque on sun-exposed skin, often mistaken for eczema or psoriasis for months.
05Bladder carcinoma in situ may present with painful urination, urinary frequency, and microscopic or visible hematuria, sometimes resembling refractory urinary tract infection.
06High-grade dysplasia in Barrett esophagus is usually asymptomatic and detected during surveillance endoscopy in patients with known long-standing gastroesophageal reflux disease.
07Anal and vulvar intraepithelial neoplasia can cause itching, burning, or a visible lesion noted by patient or clinician.
08Laryngeal carcinoma in situ may cause progressive hoarseness lasting more than 4 weeks, prompting laryngoscopy.
early warning signs
•New clustered microcalcifications on screening mammography requiring stereotactic biopsy
•Persistent abnormal cervical cytology (HSIL) or positive high-risk HPV test on routine screening
•Persistent, slowly enlarging, red scaly skin patch on sun-exposed area not responding to topical steroids over 4-6 weeks
•Microscopic hematuria on routine urinalysis in an adult over 50, especially with smoking history
•Long-standing reflux symptoms in adults over 50 warranting surveillance endoscopy of Barrett esophagus
● emergency signs
•Heavy or worsening vaginal bleeding in a patient with known cervical dysplasia — possible progression to invasive cervical cancer requiring urgent evaluation
•New visible (gross) hematuria with clots in a patient with known bladder CIS — urgent cystoscopy is required to exclude muscle-invasive progression
•Rapidly enlarging, ulcerated, or bleeding skin lesion in known Bowen disease — possible progression to invasive squamous cell carcinoma
•Progressive dysphagia, weight loss, or anemia in a patient with known Barrett high-grade dysplasia — urgent endoscopic evaluation for invasive cancer
•New palpable hard breast mass distinct from known DCIS — needs urgent imaging and biopsy to exclude invasive disease
Key tests
01
Tissue biopsy with histopathologyThe diagnostic gold standard. Confirms malignant epithelial cells confined to the epithelium without basement-membrane breach. Site-specific biopsy techniques: stereotactic core needle for breast microcalcifications, colposcopic biopsy for cervix, shave or punch for skin, cystoscopic biopsy for bladder, endoscopic biopsy for esophagus.
02
Mammography and breast ultrasound (DCIS)Detects clustered microcalcifications, branching microcalcifications, and rarely a mass that prompts biopsy. Ultrasound characterizes any associated mass and guides biopsy when needed.
03
Cervical cytology and high-risk HPV testingDetects abnormal cervical cells and identifies HPV genotypes (HPV-16, HPV-18, and other high-risk types) that drive most CIN. Used as primary screening or co-testing per current guidelines.
04
Colposcopy with directed biopsyUsed after an abnormal cervical screening test. Magnified examination of the cervix with acetic acid and Lugol's iodine identifies abnormal areas for biopsy.
05
Cystoscopy with urine cytologyDetects bladder CIS as flat, velvety, erythematous areas of urothelium that often mimic inflammation. Urine cytology has high sensitivity for high-grade urothelial cells.
06
Endoscopy with surveillance biopsies (Barrett esophagus)Detects high-grade dysplasia in patients with known Barrett esophagus. Seattle protocol four-quadrant biopsies every 2 cm.
07
Immunohistochemistry and molecular markersHormone receptor and HER2 status in DCIS, p16 immunostaining for HPV-driven CIN, Ki-67 proliferation index, and other markers refine prognosis and treatment selection.
Outlook
Prognosis for carcinoma in situ is excellent overall. 5-year survival exceeds 95% across virtually all sites with appropriate treatment, reflecting the absence of metastatic potential at diagnosis. For DCIS, 10-year breast-cancer-specific mortality is under 3%; most recurrences are local rather than systemic, and half of local recurrences are invasive disease that drive longer-term mortality risk. For CIN3, cure rates exceed 90% with excisional treatment, and progression to invasive cervical cancer is rare during surveillance. For Bowen disease, cure rates with all standard treatments are 75-95%; rare progression to invasive squamous cell carcinoma occurs in 3-5% over years. For bladder CIS, complete response to BCG therapy is achieved in 65-75% at 3 months, with progression to muscle-invasive disease in approximately 15-20% over 5 years. For high-grade dysplasia in Barrett esophagus, endoscopic therapy achieves complete eradication of intestinal metaplasia in 80-90% with low recurrence on continued surveillance. Long-term prognosis depends most on adherence to surveillance, control of underlying drivers (HPV, smoking, reflux, sun exposure), and timely treatment of recurrences. Overdiagnosis is a recognized concern — particularly for low-grade DCIS, where many lesions may never progress; this is driving the growth of active surveillance research.
Older agenon-modifiable
Most carcinomas in situ increase in incidence with age, reflecting cumulative mutational damage. Median age at DCIS diagnosis is 60; Bowen disease and bladder CIS predominate at age 65-80.
Persistent high-risk HPV infectionmodifiable
HPV vaccination reduces high-grade cervical, anal, vulvar, and oropharyngeal intraepithelial neoplasia by over 80% in vaccinated cohorts. Routine cervical and where appropriate anal cytologic screening detect lesions before invasion.
Cumulative ultraviolet exposuremodifiable
Cumulative UV is the dominant driver of cutaneous CIS. Daily sunscreen, sun-protective clothing, and avoidance of tanning beds reduce risk.
Tobacco smokingmodifiable
Smoking raises bladder CIS risk 4-7 fold and contributes to oral and laryngeal CIS. Smoking cessation reduces subsequent risk over 10-15 years, particularly for bladder cancer.
Family history and inherited cancer syndromesgenetic
BRCA1/2 carriers have substantially elevated DCIS and invasive breast cancer risk; Lynch syndrome carriers have elevated colorectal high-grade dysplasia; CDH1 mutations raise lobular breast CIS risk. Genetic counseling is recommended where syndrome is suspected.
Long-standing gastroesophageal reflux and Barrett esophagusmodifiable
Barrett esophagus precedes esophageal adenocarcinoma; high-grade dysplasia is the immediate precursor. Proton pump inhibitor therapy and surveillance endoscopy reduce progression risk.
Chronic immunosuppression markedly increases risk of HPV-driven anogenital and oropharyngeal CIS, cutaneous CIS, and other intraepithelial lesions through impaired immune surveillance.
Female reproductive factors (early menarche, late menopause, nulliparity, hormone therapy)non-modifiable
Increase lifetime estrogen exposure and modestly raise DCIS incidence. Effects are most pronounced for hormone-receptor-positive DCIS.
Cruciferous vegetables (broccoli, cauliflower, kale) which provide isothiocyanates studied for chemopreventive activity
•Adequate hydration with 2 L of water daily, particularly after bladder CIS treatment
foods to avoid
•Heavy alcohol consumption — over 2 drinks daily raises breast, esophageal, and oral CIS risk
•Tobacco in any form — accelerates bladder, oral, laryngeal, and cervical CIS
•Excessive processed and red meat — modest association with colorectal high-grade dysplasia
•Crash diets that compromise overall nutrition during and after treatment
•Herbal supplements with unproven efficacy that may interact with endocrine or immunomodulatory therapy
Compare →
01
Attend all scheduled surveillance visits — imaging, cytology, cystoscopy, or endoscopy depending on site and risk profile
02Continue endocrine therapy as prescribed for hormone-receptor-positive DCIS for the full recommended duration (typically 5 years)
03Use sun protection daily, including face, neck, hands, and any prior Bowen disease site
04Perform breast self-awareness and report any new lump, nipple change, or skin change in the breast
05Maintain a current medication list and share with all clinicians
06Report any new symptoms — abnormal bleeding, persistent pain, weight loss, dysphagia, hematuria — to your specialist team
Exercise
At least 150 minutes of moderate aerobic activity weekly and two sessions of resistance training per American Cancer Society guidelines after CIS diagnosis. Exercise improves cancer-specific and overall survival across multiple CIS sites. After surgical treatment, gradual return to activity over 2-6 weeks depending on the procedure. Walking is appropriate within days of most procedures.
